Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. We performed longitudinal single-cell immune profiling of ESKD patients with COVID-19. Transcriptome, surface proteome, and immunoreceptor sequencing data were generated on 580,040 high-quality cells, derived from 187 samples from 61 patients. For a subset of individuals, we obtained samples before and during infection, allowing intra-individual comparison. Longitudinal profiling demonstrated distinct temporal gene expression trajectories in severe/critical versus mild/moderate COVID-19. We identified a population of transcriptionally distinct monocytes that emerged in peripheral blood following glucocorticoid treatment. Evaluation of clonal T cell dynamics showed that the fastest expanding clones were enriched in known SARS-CoV-2-specific sequences and shared across multiple patients. Comparison with external datasets revealed upregulation of immune cell TGF-β pathway expression in ESKD, irrespective of COVID-19 status. Our data delineate the temporal dynamics of the immune response in COVID-19 in a high-risk population.
Temporal multi-omics analysis of COVID-19 in end-stage kidney disease
终末期肾病患者 COVID-19 的时间多组学分析
阅读:6
作者:Emily Stephenson ,Erin Macdonald-Dunlop ,Lisa M Dratva ,Rik G H Lindeboom ,Zewen Kelvin Tuong ,Win Min Tun ,Lorenz Kretschmer ,Norzawani B Buang ,Stephane Ballereau ,Mia Cabantaus ,Ana Peñalver ,Elena Prigmore ,John R Ferdinand ,Benjamin J Stewart ,Jack Gisby ,Talat H Malik ,Candice L Clarke ,Nicholas Medjeral-Thomas ,Maria Prendecki ,Stephen McAdoo ,Anais Portet ,Michelle Willicombe ,Eleanor Sandhu ,Matthew C Pickering ,Marina Botto ,Sarah A Teichmann ,Muzlifah Haniffa ,Menna R Clatworthy ,David C Thomas ,James E Peters
| 期刊: | Cell Genomics | 影响因子: | 11.100 |
| 时间: | 2025 | 起止号: | 2025 Aug 13;5(8):100918. |
| doi: | 10.1016/j.xgen.2025.100918 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
